<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386812</url>
  </required_header>
  <id_info>
    <org_study_id>STU 022017-022</org_study_id>
    <nct_id>NCT03386812</nct_id>
  </id_info>
  <brief_title>Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer</brief_title>
  <official_title>Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer Treated With Androgen Deprivation Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charles Y. C. Pak Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this pilot project is to test the hypothesis that a decline in muscle&#xD;
      strength precedes the decline in bone strength in men undergoing androgen deprivation therapy&#xD;
      (ADT) for prostate cancer. The investigators will measure changes in serum biomarkers&#xD;
      involved in muscle-bone crosstalk, anatomic changes in muscle and bone structure and strength&#xD;
      that could ultimately contribute to fractures. The findings from this research will inform&#xD;
      design of interventions to reduce falls and hip fractures in patients undergoing ADT as well&#xD;
      as application to broader populations of at risk patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-five men from urology clinic with prostate cancer will be recruited and enrolled prior&#xD;
      to initiating ADT and studied at three time points. Baseline (before first does of ADT), and&#xD;
      at approximately weeks 6 and 24 while receiving ADT for prostate cancer. Study measures will&#xD;
      be the same during each of three data acquisition time points and include ascertainment of&#xD;
      venous blood to determine serum biochemical markers of muscle and bone metabolic activity,&#xD;
      MRI and CT imaging studies to assess muscle strength, volume, composition, bone volume,&#xD;
      density and strength, and validated tests of muscle strength. Subjects will serve as their&#xD;
      own controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">November 29, 2020</completion_date>
  <primary_completion_date type="Actual">November 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle strength changes with ADT by MRI</measure>
    <time_frame>24 weeks</time_frame>
    <description>Absolute muscle fat concentration (% proton density fat fraction) following ADT therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle mass changes with ADT treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mass of the proximal quadriceps, gluteal and psoas muscles by MRI (cm2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myostatin levels following ADT therapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Myostatin ug/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volumetric density following ADT therapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measure hip bone density in cm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait speed following ADT therapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Gait speed measured in meters per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grip Strength following ADT therapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Grip strength in Kg</description>
  </primary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Men with prostate cancer prior and planning to initiate ADT therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Dx with prostate cancer and planned ADT therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Limited life expectancy&#xD;
&#xD;
          -  Inability to participate in exercise testing&#xD;
&#xD;
          -  Severe functional impairment&#xD;
&#xD;
          -  Chronic kidney disease 4 or worse&#xD;
&#xD;
          -  Hgb &lt; 9&#xD;
&#xD;
          -  Use of anti-resorptive agent&#xD;
&#xD;
          -  non-English speaking&#xD;
&#xD;
          -  Bone metastasis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>yes-based on self-representation</gender_description>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Orhan Oz, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Craig D Rubin</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>androgen deprivation therapy</keyword>
  <keyword>sarcopenia</keyword>
  <keyword>bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

